Novobiotic Pharmaceuticals, LLC

Cambridge, MA 02138

SBIR Award Summary

Total Number of Awards 35
Total Value of Awards $23MM
First Award Date 07/01/04
Most Recent Award Date 08/09/17

Key Personnel

Last Name Name Awards Contact
Ling Losee Lucy Ling 17
Staley Andrew L Staley 1
Spoering Amy Spoering 9
Moore Charles Michael Moore 1
Hughes Dallas Hughes 8 Message

35 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 08/09/17 - 07/31/18

ABSTRACT The rise of multi-drug resistant pathogens, particularly ESKAPE pathogens, is a major public health concern. One effective countermeasure against such pathogens is novel antibiotics, but the rate of antibiotic discovery has been in steady decline. One particularly promising source of novel antibiotics is microbial species because most ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-14-088
Budget: 06/01/17 - 05/31/18

This project studies the structure-activity relationship (SAR) of the newly discovered antibiotic teixobactin, with the goal of delivering a candidate that has development advantages over the parent compound. Teixobactin is an unusual depsipeptide that is the first member of a novel class of peptidoglycan synthesis inhibitors. Teixobactin target...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-14-088
Budget: 06/16/16 - 05/31/17

This project studies the structure-activity relationship (SAR) of the newly discovered antibioticteixobactin, with the goal of delivering a candidate that has development advantages over the parentcompound. Teixobactin is an unusual depsipeptide that is the first member of a novel class of peptidoglycansynthesis inhibitors. Teixobactin targets l...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-14-088
Budget: 02/01/16 - 01/31/17

? DESCRIPTION (provided by applicant): The long-term goal of this program is to develop a novel antimicrobial, teixobactin, into a therapeutic for treating a wide range of infections caused by Gram-positive pathogens. The goal of this Phase II project is to perform preclinical development of teixobactin to enable subsequent IND studies. NovoB...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 07/01/15 - 12/31/15

DESCRIPTION (provided by applicant): The overall goal of this project is to discover novel antibiotics to combat important drug-resistant pathogens. One effective countermeasure against such pathogens is novel antibiotics, but the rate of antibiotic discovery has been in steady decline. All the more recently introduced antibiotics are derivative...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 05/01/15 - 04/30/16

DESCRIPTION (provided by applicant): The overall goal of this project is to develop a selective antibiotic against Clostridium difficile, the major agent responsible for antibiotic-induced diarrhea and colitis. The pathogen can be carried in healthy individuals, and is kept at bay by gut symbionts. Antibiotic treatment suppresses the normal flor...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 02/01/15 - 07/31/15

DESCRIPTION (provided by applicant): The slow pace of antibiotic discovery is being outmatched by rapid acquisition of resistance by our pathogens. The need is especially acute in the case of Mycobacterium tuberculosis (TB), where strains of XDR-TB resistant to the majority of standard therapeutics are rapidly spreading. In a previous RO1 screen...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-14-088
Budget: 02/01/15 - 01/31/16

DESCRIPTION (provided by applicant): The long-term goal of this program is to develop a novel antimicrobial, teixobactin, into a therapeutic for treating a wide range of infections caused by Gram-positive pathogens. The goal of this Phase II project is to perform preclinical development of teixobactin to enable subsequent IND studies. NovoBiotic...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 12/01/14 - 11/30/15

DESCRIPTION (provided by applicant): The overall goal of this project is to discover novel antibiotics to combat important drug-resistant pathogens. We are running out of treatment options for pathogens such as S. aureus MRSA, vancomycin-resistant Enterococci (VRE), multidrug-resistant P. aeruginosa, A. baumannii, ESBL and New Delhi metallo-b- l...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 05/01/14 - 04/30/15

The overall goal of this project is to develop a selective antibiotic against Clostridium difficile, the major agent responsible for antibiotic-induced diarrhea and colitis. The pathogen can be carried in healthy individuals, and is kept at bay by gut symbionts. Antibiotic treatment suppresses the normal flora, but spores of C. difficile survive...

Load More